Active, not recruitingPhase 2NCT05712356
A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors
Studying Carcinoma of gallbladder and extrahepatic biliary tract
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Lisata Therapeutics, Inc.
- Principal Investigator
- Kristen K Buck, MDLisata Therapeutics, Inc.
- Intervention
- certepetide(drug)
- Enrollment
- 67 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2030
Study locations (19)
- Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
- Mayo Clinic Arizona, Phoenix, Arizona, United States
- University of Arizona Cancer Center, Tucson, Arizona, United States
- Moffitt Cancer Center, Tampa, Florida, United States
- Alliance for Multispecialty Research, Merriam, Kansas, United States
- University of Kansas Cancer Center, Westwood, Kansas, United States
- University of Kentucky Medical Center, Lexington, Kentucky, United States
- Norton Cancer Institute, Downtown, Louisville, Kentucky, United States
- Norton Cancer Institute, Audubon, Louisville, Kentucky, United States
- Mayo Clinic Rochester, Rochester, Minnesota, United States
- Northwell Health - Zuckerberg Cancer Center, Lake Success, New York, United States
- Stony Brook Cancer Center, Stony Brook, New York, United States
- FirstHealth of the Carolinas, Inc., Pinehurst, North Carolina, United States
- Carl & Edyth Lindner Center for Research & Education at The Christ Hospital and The Christ Hospital Cancer Center, Cincinnati, Ohio, United States
- Spartanburg Medical Center, Spartanburg, South Carolina, United States
- +4 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05712356 on ClinicalTrials.govOther trials for Carcinoma of gallbladder and extrahepatic biliary tract
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONPHASE2NCT06901622Camrelizumab and Chemotherapy With or Without Anlotinib as First-line Treatment for Advanced Gallbladder Cancer and Extrahepatic CholangiocarcinomaThe First Affiliated Hospital of Zhengzhou University
- RECRUITINGNCT07337850Prospective Evaluation of 68Ga-FAPI PET in Biliary CancersTata Memorial Centre
- RECRUITINGPHASE2NCT06440993Durvalumab + Intraductal Radiofrequency Ablation (ID-RFA) in Extrahepatic CholangiocarcinomaInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
- ENROLLING BY INVITATIONPHASE3NCT06671418Primary Percutaneous Stenting Above the Ampulla Versus Endoscopic Drainage for Unresectable Malignant Hilar Biliary ObstructionErasmus Medical Center
- RECRUITINGNCT05404347NGS in Gallbladder Cancer and Response to TreatmentBanaras Hindu University
See all trials for Carcinoma of gallbladder and extrahepatic biliary tract →